Applied Research Systems Ars Holding N.v.

Ottaviano Serlupi-Crescenzi

Linda Della Pietra

Anna Rita Pezzotti

Alessandro Bressan

Annarita Pezzotti

The present invention relates to IL-6 antagonist peptides, isolatable from a peptide library through the two-hybrids system by their ability to bind to the intracellular domain of gp130 and containing at least 5 amino acids. In particular, such peptides comprise the amino acid sequence SEQ ID NO: 6, as well as salts, functional derivatives, precursors and analogs thereof. The present invention also provides the peptides in substantially purified form, in order to be suitable for use in pharmaceutical compositions as active ingredient in pathologies that require IL-6 activity inhibition.

IL-6 antagonist peptides

A predominant allelic variant of the human STAT protein, the cDNA sequence encoding it, its use in therapy and/or in diagnosis of autoimmune and/or inflammatory diseases, as well as pharmaceutical compositions comprising it.

Allelic variant of human STAT3

The present invention relates to IL-6 antagonist peptides, isolatable from a peptide library through the two-hybrids system by their ability to bind to the intracellular domain of gp 130 and containing at least 5 amino acids. In particular, such peptides comprise an amino acid sequence, which is selected from the group consisting of: SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 SEQ ID NO: 8 as well as salts, functional derivatives, precursors and analogs thereof. Another object of the present invention is to provide the peptide in substantially purified form, in order to be suitable for use in pharmaceutical compositions as active ingredient in pathologies that require IL-6 activity inhibition.

An allelic variant of the human STAT3 protein and compositions comprising it are disclosed.

Growing community of inventors

Rome, Italy

Ottaviano Serlupi-Crescenzi